Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
about
Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog TherapyKASL clinical practice guidelines: management of chronic hepatitis BOutcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factorsAsian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL.Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis BDurability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis BTelbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.Virus and Host Testing to Manage Chronic Hepatitis B.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.Virological and serological tools to optimize the management of patients with chronic hepatitis B.Hepatitis B: treatment choice and monitoring for response and resistance.Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy.When can we stop nucleoside analogues in patients with chronic hepatitis B?New antivirals for the treatment of chronic hepatitis B.Predictors for efficacy of combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B.HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study.Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study.Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy.Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study.Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg.Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure.Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate.Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics.Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B.Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy.Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study.
P2860
Q26740161-BF1EBE0B-C7F2-4026-85A5-B1B97A679BD9Q26752475-AB13FD44-C631-4BD0-90FF-DFDAA1C646AAQ27020938-FDDF0759-CA8A-4EAF-95AA-5084D8ED7165Q30391932-F144D3BE-BDC1-4FFC-8438-72F658E8DEABQ33686951-48FDCB01-715C-4BE8-818F-DA5CB62C6388Q35961444-7B677831-3D26-405C-9D28-B04AA84B4461Q36195218-7A9C9EB3-4C5C-4695-AB2A-1FF1AF2C4407Q36254363-5BA5A625-8827-4514-9318-8FD1BBF78CECQ36958940-B94043C5-D76D-4907-AB1A-F7DADA22093FQ37343296-29819700-CD12-4324-A7DF-06767C9AC6FEQ37501060-CA851F92-6CD4-43BD-B5C6-BE2DCC507421Q38238547-94150D6F-BB41-48D6-BC40-57911D228D1CQ38295840-ABC96FC2-235A-44BC-A40E-D3C9D4E2AE93Q38295855-6371F0AF-64B9-4F5C-8082-3858BD1A0E24Q38543596-B3A42475-3AB0-4698-80AB-B9008BB889D2Q38648688-27130D24-1598-40BA-9CFB-C3647CFD3296Q38685589-4A16B60F-87CF-4D22-90CE-402B5302DB57Q38707903-624BF283-530F-44A9-A127-AEB7D36D6EB2Q38811832-364166FC-0CC8-4D2C-85C3-6F9E159D6D78Q38964920-C04E02FC-EA7B-400E-ABEC-23C435571BEBQ38999610-C56C7E4E-9E95-4C3F-9F05-82EEBF54033BQ39067306-DDEF652B-EEB9-4FD1-B100-CE74FB035F72Q39315990-A5CC4E3A-6A23-4C01-A898-2E073715A8E3Q40102464-86733DA5-A2BB-4618-A2AE-1C402375A516Q40161294-3FED9153-D2F1-48F3-92A7-33A8E3F15961Q40189344-DCA55740-EC54-4DAE-BDED-B6C2151D23FCQ40280136-028EC8FA-5EA6-42A0-B8D2-2B1B88F2ABA9Q40361006-0BA000BB-6D5C-414C-8483-C462D967CA12Q40423977-4A910D66-D3DB-4FBB-BB29-564909717410Q40817492-EC07514F-A8A2-49BD-8148-7138176DD5EDQ40870495-8184879A-63F0-4303-841B-013CCD33F461Q40957411-847D7911-779C-4FE2-A646-89D5C0C14759Q41121379-86C6293C-CD74-4EC3-92C7-D68E6A1269FAQ41249783-599C6BB9-394A-4C3C-9E33-E88F17306CC8Q41927231-0C17F782-D842-4972-89EB-62F95FF4EF5AQ41930574-F465023C-5E64-4C98-A200-176800DB2DDCQ47105045-8AE1FA5B-4016-48EE-B41B-524761A85193Q47142488-D8BF72ED-720B-4739-9D3D-8C2F133ECC29Q47557330-83457F9F-01ED-4FD1-A2DD-A29A830047D4Q52632456-BD9E6AFD-7F29-4F31-A0FF-A8344E598798
P2860
Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study
description
article
@en
im Mai 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2014
@uk
name
Treatment cessation of entecav ...... multicentre prospective study
@en
Treatment cessation of entecav ...... multicentre prospective study
@nl
type
label
Treatment cessation of entecav ...... multicentre prospective study
@en
Treatment cessation of entecav ...... multicentre prospective study
@nl
prefLabel
Treatment cessation of entecav ...... multicentre prospective study
@en
Treatment cessation of entecav ...... multicentre prospective study
@nl
P2093
P2860
P1433
P1476
Treatment cessation of entecav ...... multicentre prospective study
@en
P2093
Aric Josun Hui
Grace Lai-Hung Wong
Henry Lik-Yuen Chan
Kevin Sze-Hang Liu
Man-Fung Yuen
Vincent Wai-Sun Wong
P2860
P304
P356
10.1136/GUTJNL-2014-307237
P407
P577
2014-05-15T00:00:00Z